Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data?

× No keyword cloud information.

7 in total

1. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.

Authors: Romain Altwegg; Marc Ychou; Vanessa Guillaumon; Simon Thezenas; Pierre Senesse; Nicolas Flori; Thibault Mazard; Ludovic Caillo; Stéphanie Faure; Emmanuelle Samalin; Eric Assenat
Journal: World J Gastroenterol Date: 2012-03-28 Impact factor: 5.742

Review 2. Perineural invasion and associated pain in pancreatic cancer.

Authors: Aditi A Bapat; Galen Hostetter; Daniel D Von Hoff; Haiyong Han
Journal: Nat Rev Cancer Date: 2011-09-23 Impact factor: 60.716

3. A novel schedule of erlotinib/capecitabine (7/7) as salvage therapy in previously treated advanced pancreatic adenocarcinoma: a case series.

Authors: Jiezhong Chen; Kristin Kaley; Marie Carmel Garcon; Teresa Rodriguez; Muhammad Wasif Saif
Journal: Therap Adv Gastroenterol Date: 2016-03 Impact factor: 4.409

4. Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology.

Authors: Matthew J Abrams; Kevin Rakszawski; Monali Vasekar; Frank Passero; Atif Abbas; Yuxia Jia; Muhammad Wasif Saif
Journal: Therap Adv Gastroenterol Date: 2016-03 Impact factor: 4.409

5. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.

Authors: Muhammad Wasif Saif; Jia Li; Lynne Lamb; Kristin Kaley; Kyle Elligers; Zaoli Jiang; Scott Bussom; Shwu-Huey Liu; Yung-Chi Cheng
Journal: Cancer Chemother Pharmacol Date: 2013-12-03 Impact factor: 3.333

6. Study of Clinical Survival and Gene Expression in a Sample of Pancreatic Ductal Adenocarcinoma by Parsimony Phylogenetic Analysis.

Authors: Sinem Nalbantoglu; Mones Abu-Asab; Ming Tan; Xuemin Zhang; Ling Cai; Hakima Amri
Journal: OMICS Date: 2016-07

7. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.

Authors: C Yoo; J Y Hwang; J-E Kim; T W Kim; J S Lee; D H Park; S S Lee; D W Seo; S K Lee; M-H Kim; D J Han; S C Kim; J-L Lee
Journal: Br J Cancer Date: 2009-10-13 Impact factor: 7.640

7 in total